WO2004078145A3 - Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis - Google Patents

Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis Download PDF

Info

Publication number
WO2004078145A3
WO2004078145A3 PCT/US2004/006806 US2004006806W WO2004078145A3 WO 2004078145 A3 WO2004078145 A3 WO 2004078145A3 US 2004006806 W US2004006806 W US 2004006806W WO 2004078145 A3 WO2004078145 A3 WO 2004078145A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
multiple sclerosis
simvastatin
glatiramer acetate
amount
Prior art date
Application number
PCT/US2004/006806
Other languages
French (fr)
Other versions
WO2004078145B1 (en
WO2004078145A2 (en
Inventor
Liat Hayardeny
Dina Kofler
Original Assignee
Teva Pharma
Liat Hayardeny
Dina Kofler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Liat Hayardeny, Dina Kofler filed Critical Teva Pharma
Publication of WO2004078145A2 publication Critical patent/WO2004078145A2/en
Publication of WO2004078145A3 publication Critical patent/WO2004078145A3/en
Publication of WO2004078145B1 publication Critical patent/WO2004078145B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of simvastatin, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, simvastatin and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. Additionally, the subject invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of simvastatin, wherein the amounts when taken together are effective to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of simvastatin, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.
PCT/US2004/006806 2003-03-04 2004-03-04 Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis WO2004078145A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45181703P 2003-03-04 2003-03-04
US60/451,817 2003-03-04

Publications (3)

Publication Number Publication Date
WO2004078145A2 WO2004078145A2 (en) 2004-09-16
WO2004078145A3 true WO2004078145A3 (en) 2005-03-24
WO2004078145B1 WO2004078145B1 (en) 2005-05-19

Family

ID=32962640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006806 WO2004078145A2 (en) 2003-03-04 2004-03-04 Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis

Country Status (1)

Country Link
WO (1) WO2004078145A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013643A1 (en) * 2000-09-19 2004-01-22 Novlmmune S.A. Methods for treatment of multiple sclerosis with statins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013643A1 (en) * 2000-09-19 2004-01-22 Novlmmune S.A. Methods for treatment of multiple sclerosis with statins

Also Published As

Publication number Publication date
WO2004078145B1 (en) 2005-05-19
WO2004078145A2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2005084377A3 (en) Combination therapy with glatiramer acetate and riluzole
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007081975A3 (en) Method of treating multiple sclerosis
WO2007029249A3 (en) Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases
WO2010030180A3 (en) Peptide formulations and uses thereof
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CA2632207C (en) Use of calcitonin for the treatment of ra
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
TW200503668A (en) Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
JP2004537500A5 (en)
WO2006113718A3 (en) Compositions for the treatment of neoplasms
PL1656131T3 (en) Use of betaine for treating intermittent claudication
WO2010045522A3 (en) Combination therapies for the treatment of obesity
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050211

122 Ep: pct application non-entry in european phase